Importantly, a portion of patients in CH-ACM-01 who were not biochemically controlled at baseline demonstrated biochemical response by the end of the trial; the single patient in CHIASMA OPTIMAL who had an IGF-I > 1.0 × ULN at baseline, improved by the end of the trial. This evidence concerns the gene IGF1 and cyclic hematopoiesis.